Yungo Kwak
Analyst, Piper Sandler & Co.
Replay available
Immunic, Inc. (NASDAQ: IMUX) Q4 2023 earnings conference call, held 2024-02-22. Replay captured from the company's public earnings webcast.

Analyst, Piper Sandler & Co.
Analyst, Ladenburg Thalmann
Vice President, Investor Relations and Communications
Analyst, Leerink Partners
Chief Executive Officer and President
Chief Financial Officer
Analyst, B. Riley Securities
Analyst, Wedbush Securities
Good morning to everybody on the line. I would like to welcome you to Immunix's fourth quarter and year-end 2023 earnings call. My name is Jessica Bru, Vice President Investor Relations and Communications at Immunix. I will also be the moderator today. Speaking on the call are Dr. Daniel Fitt, our Chief Executive Officer and President, as well as Glenn Whaley, our Chief Financial Officer. Please note that all participants will be in listen-only mode, and this event is being recorded. After today's presentation, there will be an opportunity to ask questions. If you joined the webcast via the Zoom platform, there are two ways to submit questions. You can either submit your questions in writing via the Q&A tool of the Zoom portal, or if you would like to speak with us directly, please use the raise hand function in the Zoom portal to queue your question. Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with a similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunex's actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunix's opinions only as of the date of this presentation and it undertakes no obligation to revise or publicly release the result of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunix's SEC filings for a more detailed description of the risk factors that may affect Immunix's results and these forward-looking statements. I would now like to turn the call over to our CEO and President, Dr. Daniel Fitt, to begin the p...